Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$46.83 USD

46.83
13,546,809

-3.45 (-6.86%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $46.85 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

CRISPR Therapeutics AG (CRSP) Up 20.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy

by Zacks Equity Research

Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.

Novavax's (NVAX) Updated COVID Jab Gets WHO Nod for Emergency Use

by Zacks Equity Research

Following this authorization, Novavax's (NVAX) updated COVID-19 vaccine is available as an option to all 194 WHO member states.

Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up

by Zacks Equity Research

Arcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis.

Vertex (VRTX) Non-Cystic Fibrosis Pipeline Boosts Stock This Year

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) is likely to achieve multiple clinical milestones in late/2023 and 2024, both in its CF and non-CF portfolio.

Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Moderna (MRNA) Beats on Q3 Earnings & Sales, Expects Lower COVID Demand

by Zacks Equity Research

Moderna (MRNA) beats expectations for earnings and sales. However, the company projects lower-than-expected 2024 guidance, which likely led to a decline in share price after the earnings announcement.

Exploring Analyst Estimates for Moderna (MRNA) Q3 Earnings, Beyond Revenue and EPS

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2023.

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Repligen (RGEN) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of 64.29% and 2.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales

by Zacks Equity Research

Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.

Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline

by Zacks Equity Research

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports third-quarter earnings.

Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $79.76, moving +1.42% from the previous trading session.

Moderna (MRNA) Stock Moves -0.37%: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $86.01, marking a -0.37% move from the previous day.

Moderna (MRNA) Down Despite Maintaining COVID Jab Sales View

by Zacks Equity Research

Though Moderna (MRNA) reiterated its sales guidance for COVID vaccine, it warned investors that it could not predict exact demand yet.

Mark Vickery headshot

Markets Pop on Bargain Hunting, Stronger Economy

by Mark Vickery

The small-cap Russell 2000, still under water over the past month, led the way higher today.

J&J (JNJ) to Report Q3 Earnings, Its First After Unit Spin-Off

by Zacks Equity Research

J&J's (JNJ) third-quarter results are the first quarterly update for the new company after the Consumer Health spin-off.

Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

In the closing of the recent trading day, Moderna (MRNA) stood at $102.76, denoting a -1.6% change from the preceding trading day.

Novavax (NVAX) Focuses on Diversifying Vaccines Portfolio

by Zacks Equity Research

Owing to the slow uptake of Novavax's (NVAX) COVID-19 vaccine, the company is trying to develop other vaccine candidates targeting different indications.

Alexandria (ARE) Receives Rating Affirmation From Moody's

by Zacks Equity Research

Underpinning Alexandria's (ARE) solid operating and financial performance, Moody's Investors Service reaffirms the company's credit ratings of Baa1 and maintains its outlook rating at stable.

The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna

by Zacks Equity Research

Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna are included in this Analyst Blog.

Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More

by Zacks Equity Research

Regulatory and pipeline updates from Novavax (NVAX) and ALX Oncology Holdings (ALXO) are in focus in the biotech sector.

Moderna (MRNA) to Advance COVID/Flu Combo Jab to Late-Stage Study

by Zacks Equity Research

Moderna's (MRNA) intends to start the late-stage study on its COVID-19-influenza combination vaccine candidate before year-end. A commercial launch is expected in 2025.

Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $104.26, marking a +1.14% move from the previous day.